IL17A and COVID-19: Our results, showing that the use of biologic therapy, including anti-TNF-α agents, IL-17 blockers and anti-IL-23 agents, did not increase risk of SARS-CoV-2 infection or COVID-19 disease severity in PsD patients, are in line with these studies, including the study by Benucci et al. on the humoral response to mRNA BNT162b2 vaccine in PsA patients [9].